Jasper Therapeutics, Inc. (NASDAQ: JSPR) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $68.00 price target on the stock.
LowReport
Jasper Therapeutics, Inc. (NASDAQ: JSPR) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $68.00 price target on the stock.
Jasper Therapeutics, Inc. (NASDAQ: JSPR) is now covered by analysts at BMO Capital Markets. They set an "outperform" rating and a $63.00 price target on the stock.
MediumReport
Jasper Therapeutics, Inc. (NASDAQ: JSPR) is now covered by analysts at BMO Capital Markets. They set an "outperform" rating and a $63.00 price target on the stock.
Jasper Therapeutics, Inc. (NASDAQ: JSPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $65.00 price target on the stock.
LowReport
Jasper Therapeutics, Inc. (NASDAQ: JSPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $65.00 price target on the stock.
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
"Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ blog email newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our blog below: